Following a couple of years of growth, 2012 was a tough year for medtech companies. 2013, with the addition of the 2.3% medical device tax, did not start out any better, but the momentum of a rebound is building.

MRG analyzed the revenues of the top 25 medtech companies (counting only medical device-derived revenues for multimarket competitors, Johnson & Johnson being the primary example here), and the resulting story looks like a positive turnaround for the industry despite stumbling into 2013.

DRG becomes Clarivate

View Now